CPI-006 2 mg/kg + SOC + CPI-006 1 mg/kg + SOC + Placebo + SOC
Phase 3Terminated 0 views this week 0 watching💤 Quiet
Interest: 26/100
26
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 24
Phase 35
ApprovedIndication / Disease
Covid-19
Conditions
Covid-19
Trial Timeline
Feb 25, 2021 → Aug 18, 2021
NCT ID
NCT04734873About CPI-006 2 mg/kg + SOC + CPI-006 1 mg/kg + SOC + Placebo + SOC
CPI-006 2 mg/kg + SOC + CPI-006 1 mg/kg + SOC + Placebo + SOC is a phase 3 stage product being developed by Corvus Pharmaceuticals for Covid-19. The current trial status is terminated. This product is registered under clinical trial identifier NCT04734873. Target conditions include Covid-19.
What happened to similar drugs?
7 of 20 similar drugs in Covid-19 were approved
Approved (7) Terminated (4) Active (11)
Hype Score Breakdown
Clinical
17
Activity
0
Company
9
Novelty
0
Community
0
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT04734873 | Phase 3 | Terminated |
Competing Products
20 competing products in Covid-19
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| mRNA-1283.251 Variant-containing Formulation | Moderna | Approved | 0 |
| mRNA-1283.222 | Moderna | Phase 3 | 0 |
| COVID-19 Vaccine | Moderna | Preclinical | 0 |
| mRNA-1083 | Moderna | Phase 3 | 0 |
| SPIKEVAX (mRNA-1273) | Moderna | Preclinical | 0 |
| Moderna COVID-19 Vaccine | Moderna | Preclinical | 0 |
| Gam-COVID-Vac | Dr. Reddy's Laboratories | Phase 2/3 | 31 |
| Human COVID-19 immunoglobulin (pH4) for intravenous injection + Placebo | Sinopharm | Phase 2 | 31 |
| Mavrilimumab + Placebos | Kiniksa Pharmaceuticals | Phase 2 | 29 |
| Gimsilumab + Placebo | Roivant Sciences | Phase 2 | 32 |
| Icosapent ethyl | Amarin Corporation | Phase 2 | 25 |
| Bamlanivimab + Placebo + Etesevimab | Eli Lilly | Phase 3 | 40 |
| Infliximab | Celltrion | Phase 2 | 35 |
| CT-P63 and CT-P66 / Placebo | Celltrion | Phase 3 | 32 |
| Enzalutamide Pill | Astellas Pharma | Phase 2 | 27 |
| S-892216 + Placebo | Shionogi | Phase 2 | 35 |
| S-892216 + Carbamazepine | Shionogi | Phase 1 | 29 |
| FOY-305 + Placebo | Ono Pharmaceutical | Phase 3 | 40 |
| Desidustat | Zydus Lifesciences | Phase 2 | 35 |
| LY3819253 + Placebo | Eli Lilly | Phase 1 | 29 |